Alexion Pharmaceuticals Inc (ALXN.O) said it bought privately held biotechnology firm Taligen Therapeutics for $111 million, to expand its product portfolio. Alexion said it will provide 2011 financial outlook in February, including deal-related expenses. Adjusted research and development expenses for 2011 are expected to be about 18 percent of sales, including activities related with Taligen's programs, Alexion said in a statement.
Source
